Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure-Reference-Cited by-同舟云学术

Different effects of perindopril and enalapril on monocyte cytokine release in coronary artery disease patients with normal blood pressure

Published:2012-11 Issue:6 Volume:64 Page:1466-1475
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacological Reports

Author:

Krysiak Robert,Okopień Bogusław

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Reference27 articles.

1. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection;Abuissa;Diabetes Obes Metab,2008

2. A review of perindopril in the reduction of cardiovascular events;Campbell;Vasc Health Risk Manag,2006

3. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials;Dagenais;Lancet,2006

4. ACE inhibitors and angiotensin II receptor antagonists;Dendorfer;Handb Exp Pharmacol,2005

5. The EUROPA trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Mayo Clinic Proceedings;2022-10

2. The immunomodulatory effects of antihypertensive therapy: A review;Biomedicine & Pharmacotherapy;2022-09

3. Circadian rhythms of risk factors and management in atherosclerotic and hypertensive vascular disease: Modern chronobiological perspectives of an ancient disease;Chronobiology International;2022-06-27

4. Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers;International Journal of Molecular Sciences;2022-02-04

5. The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19;Frontiers in Pharmacology;2021-06-17